Kim Wittrup-Jensen

Economic Costs of Overactive Bladder in the United States

OBJECTIVES To calculate, from a societal perspective, current direct (medical and nonmedical) and indirect costs of overactive bladder (OAB) in the United States and project them to future years. Existing cost assessments of OAB in the United States are incomplete and outdated. METHODS A prevalence-based model was developed incorporating age- and sex-specific OAB prevalence rates, usage data, and productivity data. On the basis of the information gathered from the recent 5 years of the medical literature, practice guidelines, Medicare and managed care fee schedules, and expert panel input, the annual per capita and total US costs were calculated for 2007. US census population forecasts were used to project the costs of OAB to 2015 and 2020. RESULTS In 2007, average annual per capita costs of OAB were

Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study

1925 (

Improvement in Vision-Related Function with Intravitreal Aflibercept: Data from Phase 3 Studies in Wet Age-Related Macular Degeneration

1433 in direct medical,

A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention

66 in direct nonmedical, and

Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study.

426 in indirect costs). Applying these costs to the 34 million people in the United States with OAB results in total national costs of

Potential economic impact of increasing low dose aspirin usage on CVD in the US

65.9 billion (billion = 1000 million), (

Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.

49.1 billion direct medical,

A systematic literature review of utility weights in wet age-related macular degeneration.

2.3 billion direct nonmedical, and

Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis

14.6 billion indirect). Average annual per capita costs in 2015 and 2020 would be

Current Management and Barriers to Treatment for Wet Age-Related Macular Degeneration (Wamd): Perspectives From Patients and Caregivers

1944 and